A greater dose of ivermectin will be tested in a research aimed at treating mild-to-moderate COVID-19.
ACTIV-6, also known as "The Randomized Trial to Evaluate Efficacy of Repurposed Medications," is a double-blind, nationwide study that has attracted over 3,000 participants thus far. It is expected that enrollment will.